Beam Therapeutics (BEAM) Other financing activities (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Other financing activities data on file, last reported at $2.0 million in Q1 2026.

• On a quarterly basis, Other financing activities rose 181.64% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $6.1 million, a 735.11% increase from a year earlier, with the FY2025 full-year figure at $4.8 million, changed N/A from the prior year.
• Other financing activities for Q1 2026 stood at $2.0 million, up from $1.9 million in the prior quarter.
• Over the last five years, Other financing activities for BEAM reached as high as $30.6 million in Q4 2023 and fell as low as -$2.2 million in Q4 2024.
• Historically, Other financing activities has averaged $2.6 million across 5 years, with a median of $1.1 million in 2022.
• On a YoY basis, Other financing activities climbed as much as 2661.34% in 2023 and fell as far as 3218.52% in 2023.
• Year by year, Other financing activities stood at $1.1 million in 2022, then jumped by 2661.34% to $30.6 million in 2023, then tumbled by 107.05% to -$2.2 million in 2024, then jumped by 187.52% to $1.9 million in 2025, then climbed by 7.37% to $2.0 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $2.0 million in Q1 2026, $1.9 million in Q4 2025, and $412000.0 in Q3 2025.